{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:45:43Z","timestamp":1781246743013,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We report the first case of a patient affected by peritoneal metastases from colon cancer, arising in the context of Lynch syndrome with pathological complete response. The patient was treated with immunotherapy and cytoreductive surgery. This paper discusses the implications of these novel therapies for the management of PM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 50-year-old man affected by Lynch syndrome was referred to our institution for metachronous peritoneal recurrence of ascending colon adenocarcinoma. As a second-line treatment, he received Nivolumab therapy with stable disease. Patient underwent cytoreductive surgery with residual disease and a pathological complete response. Flow cytometry described a particular immune sub-population response. There was no evidence of disease progression after nine months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This is the first report of a Lynch patient affected by peritoneal metastases of colorectal cancer, treated with cytoreductive surgery (CRS) and resulting in a pathological complete response after immune checkpoint inhibitors treatment (ICIs). This case report may suggest that patients with peculiar immunological features could benefit from a tailored approach, since \u201cclassical\u201d CRS paradigms may not effectively predict the clinical outcome. Further large-scale studies are needed to determine the correct operative management of such patients (tailored or \u201cstandard\u201d CRS), defining the correct surgical timing and eventual discontinuation of ICI therapy after surgery.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-02084-x","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T14:02:51Z","timestamp":1641823371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed?"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-2106","authenticated-orcid":false,"given":"Marco","family":"Tonello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriana","family":"Nappo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Vassallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Di Gaetano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Davoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pizzolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"De Simoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tassinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Scapinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Pilati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Loupakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Sommariva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"issue":"8","key":"2084_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941\u201353.","journal-title":"Int J Cancer"},{"issue":"3","key":"2084_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","volume":"30","author":"J Franko","year":"2012","unstructured":"Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30(3):263\u20137.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2084_CR3","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709\u201319.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2084_CR4","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, K\u00f6hne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, \u00d6sterlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Ta\u00efeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386\u2013422.","journal-title":"Ann Oncol"},{"key":"2084_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","volume":"36","author":"F Quenet","year":"2018","unstructured":"Quenet F, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36:1.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2084_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/bjs5.50179","volume":"3","author":"S Hallam","year":"2019","unstructured":"Hallam S, Tyler R, Price M, Beggs A, Youssef H. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. BJS Open. 2019;3(5):585\u201394.","journal-title":"BJS Open"},{"issue":"5","key":"2084_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/SLA.0000000000002899","volume":"268","author":"MA Schneider","year":"2018","unstructured":"Schneider MA, Eden J, Pache B, et al. Mutations of RAS\/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC FOR peritoneal metastasis of colorectal origin. Ann Surg. 2018;268(5):845\u201353.","journal-title":"Ann Surg"},{"issue":"25","key":"2084_CR8","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1056\/NEJMra0804588","volume":"361","author":"SD Markowitz","year":"2009","unstructured":"Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449\u201360.","journal-title":"N Engl J Med"},{"issue":"12","key":"2084_CR9","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nrc1507","volume":"4","author":"JP Issa","year":"2004","unstructured":"Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4(12):988\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2084_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","volume":"100","author":"M Koopman","year":"2009","unstructured":"Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100(2):266\u201373.","journal-title":"Br J Cancer"},{"issue":"7","key":"2084_CR11","first-page":"4","volume":"13","author":"KC Birendra","year":"2017","unstructured":"Birendra KC, Hwang JJ, Farhangfar CJ, Jean Chai S. Advances in immunotherapy in the treatment of colorectal cancer. AJHO. 2017;13(7):4\u20138.","journal-title":"AJHO"},{"key":"2084_CR12","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1200\/JCO.2016.71.0012","volume":"35","author":"MB Yurgelun","year":"2017","unstructured":"Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol. 2017;35:1086\u201395.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2084_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3322\/caac.21448]","volume":"68","author":"PM Boland","year":"2018","unstructured":"Boland PM, Yurgelun MB, Boland CR. Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. CA Cancer J Clin. 2018;68(3):217\u201331. https:\/\/doi.org\/10.3322\/caac.21448].","journal-title":"CA Cancer J Clin"},{"key":"2084_CR14","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1500596.","journal-title":"N Engl J Med"},{"key":"2084_CR15","doi-asserted-by":"crossref","unstructured":"Overman MJ, Lonardi S, Leone F, et al. Nivolumab in patients with DNA mismatch repair deficient\/microsatellite instability high metastatic colorectal cancer: update from CheckMate 142. Gastroenterology Cancers Symposium 2017. [ASCO abstract 519]. J Clin Oncol. 2017;35","DOI":"10.1200\/JCO.2017.35.4_suppl.519"},{"issue":"41","key":"2084_CR16","doi-asserted-by":"publisher","first-page":"30305","DOI":"10.1074\/jbc.R600022200","volume":"281","author":"P Modrich","year":"2006","unstructured":"Modrich P. Mechanisms in eukaryotic mismatch repair. J Biol Chem. 2006;281(41):30305\u20139.","journal-title":"J Biol Chem"},{"issue":"9","key":"2084_CR17","first-page":"2447","volume":"62","author":"A Duval","year":"2002","unstructured":"Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair deficient human cancers: toward a new concept of target genes for instability. Cancer Res. 2002;62(9):2447\u201354.","journal-title":"Cancer Res"},{"issue":"26","key":"2084_CR18","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"4","key":"2084_CR19","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1053\/j.gastro.2008.01.015","volume":"134","author":"Y Schwitalle","year":"2008","unstructured":"Schwitalle Y, Kloor M, Eiermann S, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology. 2008;134(4):988\u201397.","journal-title":"Gastroenterology"},{"issue":"12","key":"2084_CR20","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","volume":"23","author":"Z Gatalica","year":"2014","unstructured":"Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2965\u201370.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"2084_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","volume":"5","author":"NJ Llosa","year":"2015","unstructured":"Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43\u201351.","journal-title":"Cancer Discov"},{"issue":"10","key":"2084_CR22","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1158\/1078-0432.CCR-14-2658","volume":"21","author":"Y Xiao","year":"2015","unstructured":"Xiao Y, Freeman GJ. A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2. Clin Cancer Res. 2015;21(10):2201\u20133.","journal-title":"Clin Cancer Res"},{"key":"2084_CR23","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol: Off J Europ Soc Med Oncol\/ESMO. 2018;29:1853\u201360.","journal-title":"Ann Oncol: Off J Europ Soc Med Oncol\/ESMO"},{"key":"2084_CR24","unstructured":"G. Takayaki S et al. Successful treatment with nivolumab for lung cancer with low expression of PD\u2010L1 and prominent tumor\u2010infiltrating B cells and immunoglobulin. Thorac Cancer 2018"},{"key":"2084_CR25","doi-asserted-by":"publisher","first-page":"101964","DOI":"10.1016\/j.ctrv.2020.101964","volume":"84","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Glynne-Jones R. How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement. Cancer Treat Rev. 2020;84:101964.","journal-title":"Cancer Treat Rev"},{"key":"2084_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s003840050072","volume":"12","author":"O Dworak","year":"1997","unstructured":"Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorect Dis. 1997;12:19\u201323.","journal-title":"Int J Colorect Dis"},{"issue":"7","key":"2084_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.it.2016.04.009","volume":"37","author":"MC Takenaka","year":"2016","unstructured":"Takenaka MC, Robson S, Quintana FJ. Regulation of the T cell response by CD39. Trends Immunol. 2016;37(7):427\u201339.","journal-title":"Trends Immunol"},{"issue":"12","key":"2084_CR28","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1158\/2159-8290.CD-19-0541","volume":"9","author":"XY Li","year":"2019","unstructured":"Li XY, Moesta AK, Xiao C, et al. Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity. Cancer Discov. 2019;9(12):1754\u201373.","journal-title":"Cancer Discov"},{"issue":"1","key":"2084_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98\u2013106.","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"2084_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/codi.13593","volume":"19","author":"CE Klaver","year":"2017","unstructured":"Klaver CE, Groenen H, Morton DG, et al. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis. 2017;19(3):224\u201336.","journal-title":"Colorectal Dis"},{"key":"2084_CR31","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","volume":"28","author":"DJ Sargent","year":"2010","unstructured":"Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219\u201326.","journal-title":"J Clin Oncol"},{"key":"2084_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/nrclinonc.2009.235","volume":"7","author":"FA Sinicrope","year":"2010","unstructured":"Sinicrope FA. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol. 2010;7:174\u20137.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2084_CR33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s40425-019-0788-5","volume":"7","author":"F Loupakis","year":"2019","unstructured":"Loupakis F, Maddalena G, Depetris I, et al. Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI\/dMMR status. J Immunother Cancer. 2019;7(1):297.","journal-title":"J Immunother Cancer"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02084-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-02084-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02084-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T14:12:23Z","timestamp":1641823943000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-02084-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2084"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-02084-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"2 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local Ethics Committee (CE IOV No. 2018\/85). Consent to participate: Written informed consent was obtained from the patient for the publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent for participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial or non-financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}